Home/Filings/4/0001213900-17-011195
4//SEC Filing

Slager David Mark 4

Accession 0001213900-17-011195

CIK 0001176309other

Filed

Oct 31, 8:00 PM ET

Accepted

Nov 1, 4:39 PM ET

Size

8.3 KB

Accession

0001213900-17-011195

Insider Transaction Report

Form 4
Period: 2017-10-31
Transactions
  • Exercise/Conversion

    Warrant (right to buy)

    2017-10-31$1.18/sh16,892$19,9260 total(indirect: By Regals Fund LP)
    Exercise: $3.77From: 2012-11-05Exp: 2017-11-05Common Stock (16,892 underlying)
  • Exercise/Conversion

    Common Stock

    2017-10-31$3.77/sh+16,892$63,6091,316,328 total(indirect: By Regals Fund LP)
Footnotes (3)
  • [F1]Mr. Slager is Managing Member of the general partner of Regals Capital Management LP ("Regals Management"). Regals Management is the investment manager of Regals Fund LP (the "Fund"). The securities reported herein are held for the account of the Fund. Pursuant to Rule 16a-1(a)(4) under the Act, Mr. Slager disclaims beneficial ownership in the securities owned by the Fund except to the extent, if any, of his pecuniary interest therein.
  • [F2]The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013.
  • [F3]The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model.

Issuer

ORAMED PHARMACEUTICALS INC.

CIK 0001176309

Entity typeother

Related Parties

1
  • filerCIK 0001477733

Filing Metadata

Form type
4
Filed
Oct 31, 8:00 PM ET
Accepted
Nov 1, 4:39 PM ET
Size
8.3 KB